Dual-incretin therapy redefining medical weight loss
Injection · Prescription
Educational content. This page describes Tirzepatide for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 30, 2026.
In SURMOUNT-1, adults without diabetes lost up to 20.9% of body weight on the treatment-regimen estimand (22.5% on the efficacy estimand) at 72 weeks, the deepest reduction reported for any approved anti-obesity medication.[7]
SURPASS-CVOT enrolled over 13,000 adults with diabetes and established cardiovascular disease and found tirzepatide noninferior to dulaglutide for major cardiovascular events, the first dedicated outcomes trial for this molecule.[13]
In SURMOUNT-OSA, tirzepatide cut the apnea-hypopnea index by roughly 25 to 29 events per hour from baseline in adults with obesity, supporting its 2024 FDA approval as the first drug for moderate-to-severe OSA.[12]
Tirzepatide is a 39-amino-acid synthetic peptide engineered from the GIP hormone backbone and modified with a C20 fatty diacid chain. That chain binds reversibly to albumin, slowing clearance and giving the molecule a half-life of about five days that supports once-weekly dosing. It is the first medicine to act as a single-molecule agonist at both the GIP and GLP-1 incretin receptors.
Eli Lilly markets it as Mounjaro for type 2 diabetes (FDA approved May 2022) and as Zepbound for chronic weight management (approved November 2023). In December 2024 the FDA expanded the Zepbound label to include moderate-to-severe obstructive sleep apnea in adults with obesity, making tirzepatide the first drug approved for that condition.
Tirzepatide is an FDA-approved branded drug rather than a research peptide. Compounded versions circulated during a 2022 to 2024 manufacturing shortage, but once the FDA declared the shortage resolved in late 2024 the broad compounding allowance wound down, and patients now typically access the branded injectable through a licensed prescriber.
GIP and GLP-1 are incretin hormones the gut releases after eating to amplify insulin secretion. Tirzepatide engages both receptors at once. The GLP-1 arm suppresses appetite, slows gastric emptying, enhances glucose-dependent insulin release, and reduces glucagon, while the GIP arm adds further insulinotropic signaling and appears to act on adipose tissue and central appetite circuits.
Pharmacology studies show the molecule is not a balanced agonist. It mimics native GIP closely at the GIP receptor but acts as a biased agonist at the GLP-1 receptor, favoring cAMP generation over beta-arrestin recruitment and receptor internalization. Researchers have proposed that this imbalanced profile contributes to its potency, though the precise human contribution of the GIP component is still debated.
In type 2 diabetes, the combined effect improves both insulin secretion and insulin sensitivity. A mechanistic analysis of SURPASS-1 monotherapy found that tirzepatide improved markers of beta-cell function and insulin sensitivity beyond what weight loss alone would predict.
Dual-incretin therapy redefining medical weight loss
Tirzepatide activates the GIP and GLP-1 receptors with a single peptide, pairing native-like GIP signaling with biased GLP-1 receptor activation. The combination enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, producing weight loss and glycemic control that exceed selective GLP-1 therapy.
At 72 weeks, body weight fell 15.0%, 19.5%, and 20.9% on 5, 10, and 15 mg (treatment-regimen estimand) versus 3.1% with placebo. The efficacy estimand reached 22.5% at the top dose.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · N Engl J Med, 387(3):205-216 (2022) · PubMed
Weight loss of 12.8% (10 mg) and 14.7% (15 mg) versus 3.2% with placebo at 72 weeks, with substantial HbA1c reduction in a population that typically loses less weight than people without diabetes.
Garvey WT, Frias JP, Jastreboff AM, et al. · Lancet, 402(10402):613-626 (2023) · PubMed
All tirzepatide doses lowered HbA1c more than semaglutide 1 mg. The 15 mg dose produced about 5.5 kg greater weight loss than semaglutide 1 mg.
Frias JP, Davies MJ, Rosenstock J, et al. · N Engl J Med, 385(6):503-515 (2021) · PubMed
After losing 20.9% during lead-in, those continuing tirzepatide lost a further 5.5% by week 88, while those switched to placebo regained 14.0%, showing weight loss depends on continued treatment.
Aronne LJ, Sattar N, Horn DB, et al. · JAMA, 331(1):38-48 (2024) · PubMed
Tirzepatide reduced the apnea-hypopnea index by 20 to 24 more events per hour than placebo at 52 weeks, supporting the first FDA drug approval for OSA.
Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med, 391(13):1193-1205 (2024) · PubMed
Major adverse cardiovascular events occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide (HR 0.92), meeting noninferiority over a median of about 4 years.
Nicholls SJ, Pavo I, Bhatt DL, et al. · N Engl J Med, 393(24):2409-2420 (2025) · PubMed
start low, go slow
Subcutaneous Injection
Subcutaneous Injection: Begin at 2.5 mg for four weeks, then increase by 2.5 mg at intervals of at least four weeks as tolerated. The 2.5 mg dose is for initiation only, not maintenance.
Dosing, titration, and the target maintenance dose are determined by a licensed provider based on your indication, response, and tolerability. The gradual escalation exists to limit gastrointestinal side effects.
Inject under the skin of the abdomen, thigh, or upper arm, rotating sites with each dose. The injection can be given at any time of day, with or without food.
If a dose is missed, it can be taken within four days; if more than four days have passed, skip it and resume the regular weekly schedule.
Trial data show that weight regain follows discontinuation, so weight management with tirzepatide is generally an ongoing rather than a short-course therapy.
Tirzepatide has been studied in more than 10,000 participants across the SURPASS and SURMOUNT programs and over 13,000 more in the SURPASS-CVOT outcomes trial. Gastrointestinal events are the most common adverse reactions and are generally mild to moderate during dose escalation.
The label carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not determined. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
Use caution with a history of pancreatitis, significant gallbladder disease, severe gastrointestinal disease such as gastroparesis, or diabetic retinopathy. Because it can delay gastric emptying, tirzepatide may reduce the absorption of oral medications, including oral contraceptives.
Tirzepatide is not recommended in pregnancy. The label advises discontinuing it at least two months before a planned pregnancy given its long half-life.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Tirzepatide | Weight Loss & Type 2 Diabetes | Injection (weekly) | Ongoing | Only dual GIP/GLP-1 agonist; the deepest weight loss of any approved obesity drug, up to about 21% of body weight |
| Semaglutide | Weight Management & Metabolic Health | Injection (weekly), Oral (daily) | Ongoing | The most clinically validated GLP-1 medicine, with outcomes data spanning weight, heart, kidney, and liver disease |
| Tesamorelin | Visceral Fat & GHRH Signaling | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog, with Phase III data in over 800 patients, documented liver-fat reduction, and physiologic pulsatile GH release |
| Ipamorelin | GH stimulation for body composition and recovery | Subcutaneous injection (1-3x daily) | Determined by provider | The most selective GH secretagogue in preclinical work: a clean GH pulse without the cortisol, prolactin, or appetite effects of older GHRPs |
| AOD-9604 | Fat Reduction (efficacy unproven in humans) | Injection (clinic practice); oral and IV in trials | Set by provider; no standard exists | Reproduces growth hormone's fat-burning domain without raising IGF-1 or impairing glucose, but failed to beat placebo for weight loss in human trials |
This peptide is an FDA-approved drug available via standard prescription.
Dual GIP/GLP-1 receptor agonist. Approved as Mounjaro (2022, diabetes) and Zepbound (2023, weight management). On April 30, 2026 the FDA proposed removing tirzepatide from the 503B bulks list and tightened documentation requirements for 503A compounding. Public comment runs through June 29, 2026.
FDA proposed excluding tirzepatide from the 503B bulks list and clarified 503A documentation standards
FDA approved Zepbound (tirzepatide) for chronic weight management
FDA approved Mounjaro (tirzepatide) for type 2 diabetes
Last verified April 30, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Tirzepatide? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling.
Approved as Ozempic and Wegovy for diabetes and chronic weight management; compounding increasingly restricted.
A stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
A selective ghrelin receptor agonist that prompts GH release without cortisol or prolactin effects.
Studied for body composition and recovery; ineligible for 503A compounding following the FDA PCAC safety review.
“Specializing in Aesthetics and Wellness ”
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering Tirzepatide.